DBV Technologies S.A. (NASDAQ:DBVT) Sees Large Decline in Short Interest

DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) saw a significant decrease in short interest during the month of April. As of April 15th, there was short interest totalling 161,900 shares, a decrease of 71.2% from the March 31st total of 561,900 shares. Approximately 0.6% of the shares of the company are sold short. Based on an average daily volume of 395,800 shares, the days-to-cover ratio is currently 0.4 days.

DBV Technologies Price Performance

NASDAQ:DBVT traded down $0.07 during trading hours on Wednesday, reaching $9.01. 47,375 shares of the company were exchanged, compared to its average volume of 183,935. The company has a market capitalization of $246.78 million, a P/E ratio of -2.00 and a beta of -0.08. The business has a 50 day moving average of $6.19 and a 200 day moving average of $4.59. DBV Technologies has a 1-year low of $2.20 and a 1-year high of $9.89.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last issued its quarterly earnings results on Friday, April 11th. The company reported ($1.10) earnings per share for the quarter. The firm had revenue of $0.51 million for the quarter. DBV Technologies had a negative return on equity of 106.07% and a negative net margin of 815.73%. As a group, equities research analysts anticipate that DBV Technologies will post -7.05 earnings per share for the current fiscal year.

Hedge Funds Weigh In On DBV Technologies

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC bought a new stake in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned about 0.24% of DBV Technologies as of its most recent SEC filing. Institutional investors own 71.74% of the company's stock.

Analysts Set New Price Targets

DBVT has been the subject of several recent research reports. StockNews.com assumed coverage on DBV Technologies in a research note on Wednesday, April 23rd. They issued a "hold" rating for the company. JMP Securities restated a "market outperform" rating and issued a $10.00 price target on shares of DBV Technologies in a research note on Friday, January 10th.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.